Hieff Trans? Liposomal 2000 Transfection Reagent 脂質(zhì)體核酸轉(zhuǎn)染試劑
產(chǎn)品名稱： Hieff Trans? Liposomal 2000 Transfection Reagent 脂質(zhì)體核酸轉(zhuǎn)染試劑
英文名稱： Hieff Trans? Liposomal 2000 Transfection Reagent 脂質(zhì)體核酸轉(zhuǎn)染試劑
產(chǎn)品編號(hào)： 40802ES
產(chǎn)品價(jià)格： 詢價(jià)
產(chǎn)品產(chǎn)地： Yeasen
品牌商標(biāo)： Yeasen
更新時(shí)間： 2025-07-17T08:32:44
使用范圍： null
- 聯(lián)系人 : 李自轉(zhuǎn)
- 地址 : 上海市浦東新區(qū)天雄路166弄一號(hào)樓三層南單元
- 郵編 : 200030
- 所在區(qū)域 : 上海
- 電話 : 139****5640 點(diǎn)擊查看
- 傳真 : 點(diǎn)擊查看
- 郵箱 : lizizhuan@yeasen.com
- 二維碼 : 點(diǎn)擊查看
Hieff Trans®脂質(zhì)體核酸轉(zhuǎn)染試劑是一種多用途的脂質(zhì)體轉(zhuǎn)染試劑，適用于DNA、RNA和寡核苷酸的轉(zhuǎn)染，對(duì)大多數(shù)真核細(xì)胞具有很高的轉(zhuǎn)染效率。其獨(dú)特的配方使其可直接加入培養(yǎng)基中，血清的存在不會(huì)影響轉(zhuǎn)染效率，這樣可以減少去除血清對(duì)細(xì)胞的損傷。轉(zhuǎn)染后不需要除去核酸-Hieff Trans®復(fù)合物或更換新鮮培養(yǎng)基，也可在4～6小時(shí)后除去。
Hieff Trans®脂質(zhì)體核酸轉(zhuǎn)染試劑以無(wú)菌的液體形式提供。通常情況下對(duì)于 24 孔板轉(zhuǎn)染，每次用1.5 μL左右，則1 mL 約可做660 次轉(zhuǎn)染；對(duì)于6孔板，每次用6 μL左右，則1 mL約可做160 次轉(zhuǎn)染。
高效性： 可對(duì)大多數(shù)真核細(xì)胞進(jìn)行轉(zhuǎn)染，并且對(duì)于常見(jiàn)細(xì)胞系轉(zhuǎn)染效率達(dá)90%以上；
低毒性：轉(zhuǎn)染細(xì)胞形態(tài)良好并表達(dá)大量的轉(zhuǎn)染基因蛋白；
操作簡(jiǎn)便：可以直接將脂質(zhì)體復(fù)合物加入到含血清的培養(yǎng)基中；
多樣性：適合瞬時(shí)轉(zhuǎn)染和穩(wěn)定轉(zhuǎn)染試驗(yàn)。
已驗(yàn)證細(xì)胞系
冰袋（wet ice）運(yùn)輸。產(chǎn)品2-8ºC保存，一年有效。不可冷凍！
Q：脂質(zhì)體轉(zhuǎn)染的效率多少，毒性如何？
A：有些細(xì)胞如 293T、293FT、Hela 等轉(zhuǎn)染效率基本在85%以上；所有陽(yáng)離子脂質(zhì)體轉(zhuǎn)染試劑對(duì)細(xì)胞都會(huì)存在一定的毒性，但是我們公司的轉(zhuǎn)染試劑經(jīng)過(guò)配方優(yōu)化后其毒性大大降低，且轉(zhuǎn)染效率也有進(jìn)一步提升。
Q：轉(zhuǎn)染試劑轉(zhuǎn)染后需要換液?jiǎn)幔?/strong>
A：對(duì)于換液可以區(qū)分兩種情況；1、轉(zhuǎn)染之前如果沒(méi)有換液應(yīng)在轉(zhuǎn)染 6 小時(shí)左右后換液，以保證細(xì)胞生長(zhǎng)所需營(yíng)養(yǎng)，2、如果轉(zhuǎn)染之前如果有換液，可以按照平時(shí)等到培養(yǎng)基出現(xiàn)營(yíng)養(yǎng)不足時(shí)換液。
Q：轉(zhuǎn)染試劑轉(zhuǎn)單個(gè)質(zhì)粒和多質(zhì)粒共轉(zhuǎn)的效率如何？
A:單轉(zhuǎn)效率對(duì)于驗(yàn)證過(guò)的細(xì)胞效率都是很好，可以參考FAQ-驗(yàn)證過(guò)的細(xì)胞系，對(duì)于共轉(zhuǎn)由于要涉及到質(zhì)粒的混合比例和質(zhì)粒與轉(zhuǎn)染試劑的添加比例問(wèn)題，因此具體的效率需要做相應(yīng)的驗(yàn)證。
Q：轉(zhuǎn)染試劑可以凍存嗎？
A:不可以凍存，因?yàn)檗D(zhuǎn)染試劑是一種脂質(zhì)體陽(yáng)離子轉(zhuǎn)染試劑，由于脂質(zhì)體是不能在低溫下凍存，因此轉(zhuǎn)染試劑最好是 4 度儲(chǔ)存，保持最好的轉(zhuǎn)染效能。
Q：轉(zhuǎn)染實(shí)驗(yàn)過(guò)程中是否需要更換成無(wú)血清培養(yǎng)基？
A：不需要，我們的轉(zhuǎn)染試劑可以在含血清的介質(zhì)中進(jìn)行轉(zhuǎn)染的過(guò)程。
Q：轉(zhuǎn)染后需要進(jìn)行終止反應(yīng)嗎？
A：不需要。脂質(zhì)體復(fù)合物可以穩(wěn)定存在 6 個(gè)小時(shí)。如果在進(jìn)行轉(zhuǎn)染前沒(méi)有進(jìn)行細(xì)胞換
Q: 這款脂質(zhì)體轉(zhuǎn)染試劑的濃度是多少？
A: 這款脂質(zhì)體轉(zhuǎn)染試劑濃度是10mg/mL。
[1] Liu R, Yang J, Yao J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022;40(5):779-786. doi:10.1038/s41587-021-01112-1(IF:54.908)
[2] Fan Y, Wang J, Jin W, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021;20(1):25. Published 2021 Feb 2. doi:10.1186/s12943-021-01321-x(IF:27.401)
[3] Tao R, Zhao Y, Chu H, et al. Genetically encoded fluorescent sensors reveal dynamic regulation of NADPH metabolism. Nat Methods. 2017;14(7):720-728. doi:10.1038/nmeth.4306(IF:25.062)
[4] Zhang Q, He X, Yao S, et al. Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency. Nucleic Acids Res. 2021;49(8):4689-4704. doi:10.1093/nar/gkab228(IF:16.971)
[5] Liang Y, Lu Q, Li W, et al. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021;49(15):8556-8572. doi:10.1093/nar/gkab626(IF:16.971)
[6] Wu S, Cao R, Tao B, et al. Pyruvate Facilitates FACT-Mediated γH2AX Loading to Chromatin and Promotes the Radiation Resistance of Glioblastoma. Adv Sci (Weinh). 2022;9(8):e2104055. doi:10.1002/advs.202104055(IF:16.806)
[7] Luo Q, Wu X, Zhao P, et al. OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. Adv Sci (Weinh). 2021;8(8):2002874. Published 2021 Feb 8. doi:10.1002/advs.202002874(IF:16.806)
[8] Chen S, Cao X, Zhang J, Wu W, Zhang B, Zhao F. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022;9(8):e2103817. doi:10.1002/advs.202103817(IF:16.806)
[9] Yan JM, Zhang WK, Yan LN, Jiao YJ, Zhou CM, Yu XJ. Bunyavirus SFTSV exploits autophagic flux for viral assembly and egress. Autophagy. 2022;18(7):1599-1612. doi:10.1080/15548627.2021.1994296(IF:16.016)
[10] Xu X, Zhang J, Tian Y, et al. CircRNA inhibits DNA damage repair by interacting with host gene. Mol Cancer. 2020;19(1):128. Published 2020 Aug 24. doi:10.1186/s12943-020-01246-x(IF:15.302)
[11] Huang K, Chen X, Li C, et al. Structure-based investigation of fluorogenic Pepper aptamer. Nat Chem Biol. 2021;17(12):1289-1295. doi:10.1038/s41589-021-00884-6(IF:15.040)
[12] Li T, Chen X, Qian Y, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021;12(1):615. Published 2021 Jan 27. doi:10.1038/s41467-021-20913-1(IF:14.919)
[13] Liu Z, Chen S, Lai L, Li Z. Inhibition of base editors with anti-deaminases derived from viruses. Nat Commun. 2022;13(1):597. Published 2022 Feb 1. doi:10.1038/s41467-022-28300-0(IF:14.919)
[14] Wu C, Wang C, Zheng J, et al. Vacuolization in Cytoplasm and Cell Membrane Permeability Enhancement Triggered by Micrometer-Sized Graphene Oxide. ACS Nano. 2015;9(8):7913-7924. doi:10.1021/acsnano.5b01685(IF:12.881)
[15] Zou Y, Wang A, Shi M, et al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018;13(10):2362-2386. doi:10.1038/s41596-018-0042-5(IF:12.423)
[16] Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020;11(1):2984. Published 2020 Jun 12. doi:10.1038/s41467-020-16799-0(IF:12.121)
[17] Song L, Liu Z, Hu HH, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun. 2020;11(1):5842. Published 2020 Nov 17. doi:10.1038/s41467-020-19694-w(IF:12.121)
[18] Shui S, Zhao Z, Wang H, Conrad M, Liu G. Non-enzymatic lipid peroxidation initiated by photodynamic therapy drives a distinct ferroptosis-like cell death pathway. Redox Biol. 2021;45:102056. doi:10.1016/j.redox.2021.102056(IF:11.799)
[19] Du L, Xie Y, Zheng K, et al. Oxidative stress transforms 3CLpro into an insoluble and more active form to promote SARS-CoV-2 replication [published online ahead of print, 2021 Nov 26]. Redox Biol. 2021;48:102199. doi:10.1016/j.redox.2021.102199(IF:11.799)
[20] Cen M, Ouyang W, Zhang W, et al. MitoQ protects against hyperpermeability of endothelium barrier in acute lung injury via a Nrf2-dependent mechanism. Redox Biol. 2021;41:101936. doi:10.1016/j.redox.2021.101936(IF:11.799)
[21] Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020;11(1):2984. Published 2020 Jun 12. doi:10.1038/s41467-020-16799-0(IF:11.614)
[22] Liu W, Zhan Z, Zhang M, et al. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. Theranostics. 2021;11(13):6278-6292. Published 2021 Apr 15. doi:10.7150/thno.57455(IF:11.556)
[23] Hao Q, Li J, Zhang Q, et al. Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma. Clin Transl Med. 2021;11(8):e500. doi:10.1002/ctm2.500(IF:11.492)
[24] Zhang Y, Yu X, Sun R, et al. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022;12(2):e684. doi:10.1002/ctm2.684(IF:11.492)
[25] Liu Z, Chen S, Xie W, et al. Versatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9. Mol Ther. 2022;30(1):256-267. doi:10.1016/j.ymthe.2021.06.013(IF:11.454)
[26] Tang X, Deng Z, Ding P, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022;41(1):85. Published 2022 Mar 8. doi:10.1186/s13046-022-02276-7(IF:11.161)
[27] Gu C, Wang Y, Zhang L, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):11. Published 2022 Jan 6. doi:10.1186/s13046-021-02220-1(IF:11.161)
[28] Chen P, Zhou J, Wan Y, et al. A Cas12a ortholog with stringent PAM recognition followed by low off-target editing rates for genome editing. Genome Biol. 2020;21(1):78. Published 2020 Mar 25. doi:10.1186/s13059-020-01989-2(IF:10.806)